Summary

Amends federal public health law to explicitly treat human cadaveric islets used for transplantation like pancreas transplants under the Public Health Service Act, and to state that those islets are not to be regulated as drugs, biological products, or HCT/Ps. Requires the Department of Health and Human Services to update its regulations to reflect this classification within one year and to report progress to Congress within six months.

• Explicitly adds human cadaveric islets to the Public Health Service Act category that covers pancreas transplants.
• Specifies that cadaveric islets are not to be treated as drugs, biological products, or HCT/Ps under federal law.
• Directs HHS to update applicable HHS and FDA regulations to implement the reclassification within one year.
• Requires a progress report to Congress from HHS within six months of enactment.
• Does not appropriate funds or create new federal spending programs; it is a definitional and regulatory change.
• Affects regulatory oversight and the administrative pathway for islet transplantation, potentially changing which federal rules apply.
• Focuses on transplantation of cadaveric islets (not on manufactured or expanded islet products).